Description

Indication & Scope

Imatinib Mesylate Tablets (Glivec®) is first-generation multi-target tyrosine kinase inhibitor. It selectively blocks BCR-ABL fusion kinase, c-KIT and PDGFR, inhibits abnormal downstream signaling, suppresses proliferation and induces apoptosis of Ph-positive leukemia and c-KIT mutant GIST tumor cells.

Mechanism
Inhibit BCR-ABL, c-KIT and PDGFR kinases, block oncogenic signal transduction
Drug class
First-generation oral multi-targeted tyrosine kinase inhibitor
Clinical use
Philadelphia chromosome-positive leukemia, c-KIT positive gastrointestinal stromal tumor and related myeloproliferative disorders

Specification

Generic Name	Imatinib Mesylate Tablets
Brand Name	Glivec®
Ingredient	Imatinib Mesylate
Dosage Form	Film-coated Tablets
Package	0.1g*60 tablets/box
Conditions Treated	Hematological malignancies: Ph+ chronic myeloid leukemia(CML), Ph+ acute lymphoblastic leukemia(ALL), myelodysplastic/myeloproliferative neoplasms, hypereosinophilic syndromeSolid tumors: unresectable/metastatic gastrointestinal stromal tumor(GIST), adjuvant therapy for resected GIST
Taboos	Hypersensitivity to imatinib or excipients, pregnancy and lactation
Place of origin	Wehr, Germany
Priscription Type	Prescription drug (Rx)
Storage Conditions	Store below 30°C, sealed and light-proof
Manufacturer	Novartis Pharma Produktions GmbH
Registration Authority	National Medical Products Administration (NMPA)
Approval number	HJ20150112
Approval Date	September 27, 2023
Shelf Life	36 months

How to use ?

Recommended Dose: Chronic-phase CML: 400mg once daily orally; accelerated/blastic phase CML: 600mg once daily; Adult Ph+ ALL: 600mg daily; Unresectable/metastatic GIST: 400–600mg daily; adjuvant GIST treatment: 400mg daily for 3 years; Dose adjustment: Reduce dosage or suspend administration for severe hematologic or non-hematologic toxicities

Time: Take with large glass of water, with meals to reduce gastrointestinal irritation; continuous administration until disease progression or intolerable toxicity

Interaction: Avoid strong CYP3A4 inhibitors/inducers; adjust dose when combined with warfarin

Side effects: Edema, nausea, diarrhea, muscle cramp, fatigue, rash, myelosuppression; severe risks: severe fluid retention, liver injury, congestive heart failure

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

Why should patients take imatinib with meals?

To decrease gastrointestinal adverse reactions.

What core target does imatinib act on for CML treatment?

BCR-ABL fusion tyrosine kinase.

What long-term adjuvant indication does it have?

Postoperative adjuvant therapy for resected GIST.

What is the treatment cycle characteristic of imatinib?

Continuous daily oral administration without fixed off-treatment cycle.

Glivec® | Imatinib Mesylate Tablets | CML, GIST and ALL | DengYueRX

INN: Imatinib Mesylate
Indications: CML (Chronic Myeloid Leukemia), GIST (Gastrointestinal Stromal Tumor) and ALL (Acute Lymphoblastic Leukemia)
Dosage Form: Film-coated Tablets
Strength: 0.1g/Tablet

Original price was: $905.29.Current price is: $769.50.